Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis
Liver International · 2025
DOI: 10.1111/liv.16222 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Liver International, 2025. Verfasst von Edoardo G Giannini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy. Hauptthemen laut MEDLINE: Chenodeoxycholic Acid, Liver Cirrhosis, Biliary, Ursodeoxycholic Acid, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background & Aims Approximately 40% of patients with Primary Biliary Cholangitis (PBC) show incomplete response to ursodeoxycholic acid, thus needing second‐line treatment to prevent disease progression. As no head‐to‐head comparison study is available, we used a network meta‐analysis (NMA) to compare efficacy and safety of available second‐line therapies.
Methods
We performed a systematic literature review including randomised, placebo‐controlled trials of patients with PBC and incomplete response, or intolerance, to ursodeoxycholic acid, and compared relative risks (RRs) for primary (biochemical response at 52‐week) and secondary outcomes [incidence of new‐onset pruritus and serious adverse events (SAEs)].
Results
The NMA included three studies, each testing obeticholic acid (OCA), seladelpar or elafibranor versus placebo (active therapy/placebo: 379/191 patients). All treatments significantly increased the RR for biochemical response with an advantage of elafibranor versus seladelpar (RR: 4.37, 95% CI: 1.01–18.87). OCA 5–10 mg/10 mg was associated with a higher risk of new‐onset pruritus compared to placebo (RR: 1.43; 95% CI: 1.09–1.88/RR: 1.79; 95% CI: 1.37–2.33), while seladelpar decreased this risk (RR: 0.30; 95% CI: 0.12–0.80). Compared to placebo, OCA 5–10 mg/10 mg was associated with an increased risk of SAE (RR: 3.82; 95% CI: 1.46–10.02/RR 2.67; 95% CI: 1.00–7.08).
Conclusions
Among second line therapies for patients with PBC, elafibranor is slightly more effective in obtaining biochemical response than seladelpar that, on the other hand, is the only drug associated with a lower incidence of pruritus. While of similar efficacy, OCA was associated with increased pruritus and SAEs. These findings may help personalise second‐line treatment in patients with PBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.
- Gastroenterology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
- Liver Center, Digestive Diseases Section, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Edoardo G Giannini, Andrea Pasta, Francesco Calabrese, Sara Labanca, Simona Marenco, Giulia Pieri, Maria Corina Plaz Torres, Mario Strazzabosco
Förderung
- NIDDK NIH HHS
Zitieren
APA
Giannini, E. G., Pasta, A., Calabrese, F., Labanca, S., Marenco, S., Pieri, G., Plaz Torres, M. C., & Strazzabosco, M. (2025). Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis. Liver International. https://doi.org/10.1111/liv.16222
Vancouver
Giannini EG, Pasta A, Calabrese F, Labanca S, Marenco S, Pieri G, et al. Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis. Liver International. 2025. doi:10.1111/liv.16222
BibTeX
@article{Giannini2025,
author = {Giannini, Edoardo G and Pasta, Andrea and Calabrese, Francesco and Labanca, Sara and Marenco, Simona and Pieri, Giulia and Plaz Torres, Maria Corina and Strazzabosco, Mario},
title = {Second‐Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta‐Analysis},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.16222}
}
EUVIMED